...
首页> 外文期刊>Prehospital emergency care >Subcutaneous epinephrine in the prehospital setting.
【24h】

Subcutaneous epinephrine in the prehospital setting.

机译:院前环境中的皮下肾上腺素。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: To outline current practice regarding the prehospital use of subcutaneous epinephrine, and systematically review the existing literature to determine the level of support for its use in the elderly. Many health care personnel are reluctant to administer subcutaneous epinephrine for potentially life-threatening conditions such as asthma and anaphylaxis in older patients. This sytematic review examined the following focused question: "For older patients not known to have coronary artery disease, does administration of subcutaneous epinephrine carry a significant enough risk of cardiovascular side effects to mandate age as a relative contraindication to self-administration or emergency medical services administration in the prehospital setting?" METHODS: The MEDLINE and Health Star databases were searched to identify studies evaluating the use of subcutaneous epinephrine in the treatment of asthma and anaphylaxis. Bibliographies from included studies, known reviews, and textbooks were examined to identify additional studies. The strength of evidence presented in each study was assessed in accordance with the classification system proposed by the American Heart Association's Emergency Cardiovascular Care Committee. RESULTS: The review of the literature revealed only three case reports (level VII evidence) that record adverse reactions of epinephrine when used for anaphylaxis and allergy, while several level III and V studies found no adverse effects when used for asthma. No controlled trials documenting adverse effects were found. CONCLUSIONS: The authors did not find significant evidence to contraindicate the use of subcutaneous epinephrine in older patients who are not known to have coronary artery disease, who present with either asthma or allergic reactions.
机译:目的:概述目前在院前使用皮下肾上腺素的做法,并系统地回顾现有文献,以确定对其在老年人中使用的支持水平。许多医疗保健人员不愿为可能危及生命的疾病(例如老年患者的哮喘和过敏反应)使用皮下肾上腺素。这项系统性的综述研究了以下重点问题:“对于未知的未患有冠心病的老年患者,皮下肾上腺素的给药是否会带来足够的心血管副作用风险,以至于将年龄定为自我给药或紧急医疗服务的相对禁忌症在院前环境中进行管理?”方法:检索MEDLINE和Health Star数据库,以鉴定评估皮下肾上腺素在哮喘和过敏反应治疗中的应用的研究。对包括研究,已知评论和教科书的参考书目进行了研究,以确定其他研究。根据美国心脏协会紧急心血管护理委员会提议的分类系统,评估了每项研究中提供的证据强度。结果:文献综述仅显示了三例病例报告(VII级证据),它们记录了肾上腺素用于过敏和过敏反应的不良反应,而一些III级和V级研究发现,用于哮喘的无不良反应。没有发现不良反应的对照试验。结论:作者没有发现明显的证据表明在患有哮喘或变态反应的不知道患有冠状动脉疾病的老年患者中禁忌使用皮下肾上腺素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号